A randomized placebo-controlled polysomnographic study of eszopiclone in Japanese patients with primary insomnia

Sleep Medicine

Volumn 13, Issue 10, 2012, Pages 1247-1253

  Uchimura, Naohisa ^a   Kamijo, Atsushi ^b   Kuwahara, Hiroo ^a   Uchiyama, Makoto ^c   Shimizu, Tetsuo ^d   Chiba, Shigeru ^e   Inoue, Yuichi ^f  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b EISAI CO LTD   (Japan)

^c NIHON UNIVERSITY   (Japan)

^d AKITA UNIVERSITY   (Japan)

^e ASAHIKAWA MEDICAL COLLEGE   (Japan)

^f TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Eszopiclone; Japanese; Polysomnography; Primary insomnia; Sleep latency; WASO

Indexed keywords

ESZOPICLONE; PLACEBO; ZOLPIDEM;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; FEMALE; FIRST DEGREE ATRIOVENTRICULAR BLOCK; HUMAN; INSOMNIA; JAPANESE; MAJOR CLINICAL STUDY; MALE; POLYSOMNOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REM SLEEP; RHINOPHARYNGITIS; SINUS BRADYCARDIA; SLEEP QUALITY; SLEEP TIME; SLOW WAVE SLEEP; TREATMENT RESPONSE;

ADULT; AZABICYCLO COMPOUNDS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; JAPAN; MALE; MIDDLE AGED; PIPERAZINES; POLYSOMNOGRAPHY; SLEEP INITIATION AND MAINTENANCE DISORDERS; YOUNG ADULT;

EID: 84870572168     PISSN: 13899457     EISSN: 18785506     Source Type: Journal    
DOI: 10.1016/j.sleep.2012.08.015     Document Type: Article

References (36)

1. Doi Y. Epidemiologic research on insomnia in the general Japanese populations [Japanese]. Nihon Rinsho 2009, 67:1463-1467.
2. US Department of Health and Human Services, National Institutes of Health NIH state-of-the-science conference statement on manifestations and management of chronic insomnia in adults. NIH Consens Sci Statements 2005, 22(2):1-30. http://consensus.nih.gov/2005/insomniastatement.pdf/ [accessed 23.11.11].
3. Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med 2007, 3(5, Suppl.):S7-S10.
4. Kessler R.C., Berglund P.A., Coulouvrat C., Hajak G., Roth T., Shahly V., et al. Insomnia and the performance of US workers: results from the America insomnia survey. Sleep 2011, 34:1161-1171.
5. Sarsour K., Kalsekar A., Swindle R., Foley K., Walsh J.K. The association between insomnia severity and healthcare and productivity costs in a health plan sample. Sleep 2011, 34:443-450.
6. Daley M., Morin C.M., LeBlanc M., Grégoire J.P., Savard J., Baillargeon L., et al. Insomnia and its relationship to health-care utilization, work absenteeism, productivity and accidents. Sleep Med 2009, 10:427-438.
7. Kleinman N.L., Brook R.A., Doan J.F., Melkonian A.K., Baran R.W. Health benefit costs and absenteeism due to insomnia from the employer's perspective: a retrospective, case-control, database study. J Clin Psychiatry 2009, 70:1098-1104.
8. Sasai T., Inoue Y., Komada Y., Nomura T., Matsuura M., Matsushima E., et al. Effects of insomnia and sleep medication on health-related quality of life. Sleep Med 2010, 11:452-457.
9. Doi Y., Minowa M., Tango T. Impact and correlates of poor sleep quality in Japanese white-collar employees. Sleep 2003, 26:467-471.
10. Asai T., Kaneita Y., Uchiyama M., Takemura S., Asai S., Yokoyama E., et al. Epidemiological study of the relationship between sleep disturbances and somatic and psychological complaints among the Japanese general population. Sleep Biol Rhythms 2006, 4:55-62.
11. Owen R.T. Eszopiclone: an update on its use in insomnia. Drugs Today 2011, 47:263-275.
12. Lunesta [package insert]. Marlborough, MA: Sunovion Pharmaceuticals Inc.; 2010.
13. Zammit G.K., McNabb L.J., Caron J., Amato D.A., Roth T. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin 2004, 20:1979-1991.
14. Walsh J.K., Krystal A.D., Amato D.A., Rubens R., Caron J., Wessel T.C., et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep 2007, 30:959-968.
15. Roth T., Walsh J.K., Krystal A., Wessel T., Roehrs T.A. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med 2005, 6:487-495.
16. McCall W.V., Erman M., Krystal A.D., Rosenberg R., Scharf M., Zammit G.K., et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Curr Med Res Opin 2006, 22:1633-1642.
17. Soares C.N., Joffe H., Rubens R., Caron J., Roth T., Cohen L. Obstet Gynecol 2006, 108:1402-1410.
18. Pollack M., Kinrys G., Krystal A., McCall W.V., Roth T., Schaefer K., et al. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry 2008, 65:551-562.
19. Fava M., McCall W.V., Krystal A., Wessel T., Rubens R., Caron J., et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 2006, 59:1052-1060.
20. Erman M.K., Zammit G., Rubens R., Schaefer K., Wessel T., Amato D., et al. A polysomnographic placebo-controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia. J Clin Sleep Med 2008, 4:229-234.
21. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use, ICH harmonised tripartite guideline 'Ethnic factors in the acceptability of foreign clinical data E5(R1)'. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E5_R1/Step4/E5_R1__Guideline.pdf.
22. Wood A.J., Zhou H.H. Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet 1991, 20:350-373.
23. Bjornsson T.D., Wagner J.A., Donahue S.R., Harper D., Karim A., Khouri M.S., et al. A review and assessment of potential sources of ethnic differences in drug responsiveness. J Clin Pharmacol 2003, 43:943-967.
24. American Psychiatric Association Diagnostic and statistical manual of mental disorders - text revision (DSM-IV-TR) 2000, American Psychiatric Press Inc., Washington, DC. 4th ed.
25. A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects 1968, U.S. National Institute of Neurological Diseases and Blindness, Neurological Information Network, Bethesda, MD, NIH Publication No. 204. A. Rechtschaffen, A. Kales (Eds.).
26. Krystal A.D., Walsh J.K., Laska E., Caron J., Amato D.A., Wessel T.C., et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003, 26:793-799.
27. Carskadon M.A., Dement W.C., Mitler M.M., Guilleminault C., Zarcone V.P., Spiegel R. Self-reports versus sleep laboratory findings in 122 drug-free subjects with complaints of chronic insomnia. Am J Psychiatry 1976, 133:1382-1388.
28. Kryger M.H., Steljes D., Pouliot Z., Neufeld H., Odynski T. Subjective versus objective evaluation of hypnotic efficacy: experience with zolpidem. Sleep 1991, 14:399-407.
29. Armitage R., Trivedi M., Hoffmann R., Rush A.J. Relationship between objective and subjective sleep measures in depressed patients and healthy controls. Depress Anxiety 1997, 5:97-102.
30. Scharf M.B., Roth T., Vogel G.W., Walsh J.K. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 1994, 55:192-199.
31. Ozone M., Yagi T., Itoh H., Tamura Y., Inoue Y., Uchimura N., et al. Effects of zolpidem on cyclic alternating pattern, an objective marker of sleep instability, in Japanese patients with psychophysiological insomnia: a randomized crossover comparative study with placebo. Pharmacopsychiatry 2008, 41:106-114.
32. Monti J.M., Pandi-Perumal S.R. Eszopiclone: its use in the treatment of insomnia. Neuropsychiatr Dis Treat 2007, 3:441-453.
33. A receptor modulating medications. Sleep 2010, 33:859-860.
34. Brunello N, Cooper J, Bettica P, Maier G, Nutt D. Differential pharmacological profiles of the GABAA receptor modulators zolpidem, zopiclone, eszopiclone, and (S)-desmethylzopiclone. In: Presented at international congress of the world psychiatry association, April 1-4, 2009, Florence, Italy. World Physchiatric 2009;8(Suppl. 1):Abstract PO2.152.
35. Hanson S.M., Morlock E.V., Satyshur K.A., Czajkowski C. Structural requirements for eszopiclone and zolpidem binding to the γ-aminobutyric acid type-A (GABAA) receptor are different. J Med Chem 2008, 51:7243-7252.
36. Fava M., Schaefer K., Huang H., Wilson A., Iosifescu D.V., Mischoulon D., et al. A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression. J Clin Psychiatry 2011, 72:473-479.